On February 3, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, reported that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company’s proprietary drug candidate RCC-33 for Colorectal cancer in nude-mice (Press release, Cannabics Pharmaceuticals, FEB 3, 2021, View Source [SID1234574553]). The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice. Both groups were
inoculated with colorectal cancer cells. Daily doses of intraperitoneal (IP) delivery of RCC-33 or sham were initiated on day 5. Differences in tumor volume between the
two groups were first observed after 5 days of treatment (day 10). Interim results of a 27% reduction in tumor volume were recorded after 12 days of treatment (day 17),
with p-value=0.022. Study is ongoing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Effect of Cannbics TM RCC-33 on Tumor Development in Mice Inoculated with Human Colorectal Cancer Cells
Effect of Cannbics TM RCC-33 on Tumor Development in Mice Inoculated with Human Colorectal Cancer Cells
Gabriel Yariv, Cannabics Pharmaceuticals’ President and COO said: "Developing innovative formulations to combat colorectal cancer is a worthy cause. Colorectal cancer is the third most diagnosed cancer worldwide and the second most lethal. That said, 67% of colorectal cancer patients undergoing currently available treatments survive for 5 years or longer. Accordingly, our objective with RCC-33 is to be able to demonstrate its efficacy and enter an official FDA track, eventually reaching a position where we can potentially help a large group of people get better and live longer; this is our ultimate goal and today marks an important step in the right direction."
Dr. Eyal Ballan, Cannabics Pharmaceuticals Co-founder and CTO said: "Today’s interim results mark an important milestone for the company. Seeing our formulation cause attenuation in tumor growth, in-vivo, and already within 12 days of treatment, is a clear indicator and an encouragement for us to continue with our focus and efforts in the direction we chose and believe in."